



INDIAN PHARMACOPOEIA COMMISSION

National Coordination Centre- Pharmacovigilance Programme of India (PvPI)

MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA

SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.

Tel No: 0120- 2783392, 2783400, 2783401, Fax: 0120-2783311

e-mail: pvpi.ipc@gov.in, ipclab@vsnl.net, Web: www.ipc.gov.in

File No. IPC/NCC-PvPI/DSA/2018-19/01

30th January 2018

Drug Safety Alerts

The preliminary analysis of ADRs from the PvPI database reveals that the following drugs may be associated with the risks as given below.

Table

Sl. No	Suspected Drugs	Indication	Adverse Reactions
1	Levetiracetam	For treatment of myoclonus-generalised epilepsy with photosensitivity, idiopathic epilepsy – control of generalised tonic clonic seizures, postanoxic and post-encephalitic myoclonic epilepsy; epileptic encephalopathies; severe myoclonic epilepsy, absence seizure; rolandic epilepsy	Hypokalaemia

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above adverse events associated with the use of above drugs. If such events are encountered please report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/ Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>) or by PvPI Helpline No. **1800-180-3024**.